Assetmark Inc. Has $32.74 Million Position in IDEXX Laboratories, Inc. $IDXX

Assetmark Inc. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,251 shares of the company’s stock after selling 13,534 shares during the period. Assetmark Inc. owned about 0.06% of IDEXX Laboratories worth $32,744,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Blalock Williams LLC acquired a new position in shares of IDEXX Laboratories during the third quarter valued at about $590,000. New York State Common Retirement Fund lifted its stake in IDEXX Laboratories by 6.8% during the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after acquiring an additional 3,820 shares in the last quarter. Arkadios Wealth Advisors purchased a new position in IDEXX Laboratories during the 2nd quarter worth $405,000. Mediolanum International Funds Ltd boosted its holdings in IDEXX Laboratories by 14.5% during the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after acquiring an additional 4,909 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after acquiring an additional 187,967 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares in the company, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 2.0%

IDXX stock opened at $629.35 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a market capitalization of $50.25 billion, a price-to-earnings ratio of 48.15, a price-to-earnings-growth ratio of 3.75 and a beta of 1.67. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The business’s 50 day moving average price is $684.99 and its two-hundred day moving average price is $667.02.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the business earned $2.53 earnings per share. The firm’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and set a $830.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Morgan Stanley increased their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. BTIG Research decreased their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. Finally, Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 7th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.